AbSci Revenue and Competitors
Estimated Revenue & Valuation
- AbSci's estimated annual revenue is currently $6.1M per year.
- AbSci's estimated revenue per employee is $22,362
- AbSci's total funding is $237.9M.
- AbSci's current valuation is $614.8M. (January 2022)
- AbSci has 271 Employees.
- AbSci grew their employee count by 28% last year.
AbSci Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is AbSci?
AbSci is a global leader in biomanufacturing technologies. The companyￃﾢ￢ﾂﾬ￢ﾄﾢs SoluProￃﾢ￢ﾀﾞￂﾢ expression platform achieves ultra-high yields of soluble and active protein products and enables ultra-high efficiency purification processes. AbSciￃﾢ￢ﾂﾬ￢ﾄﾢs unique approach accelerates drug discovery timelines, increases manufacturing efficiencies, and drastically reduces costs for the biopharmaceutical industry. We are a fearless, intellectually energetic team of scientists continually defining the future of drug discovery and manufacturing for the biopharmaceutical industry. We welcome passionate, imaginative and accomplished scientists who are risk takers, keen to experiment, collaborate and create extraordinary drug discovery and manufacturing tools to disrupt and transform how life-changing biologics are made.keywords:N/A
Number of Employees
Employee Growth %
Absci logo Absci Co. (NASDAQ:ABSI Get Rating) was the recipient of a large increase in short interest during the month of March.
Absci to present in-silico drug discovery technology at NVIDIA GTC. Breakthrough ML achievements highlight the viability of the...
Vancouver-based Absci presented its newest machine learning models this week, displaying a computer-generated model that can predict with...
Absci CEO and founder Sean McClain rings the closing bell on the NASDAQ on Thursday with his team as the Vancouver, Wash.-based biotech company went public. (Absci Photo) Biotech CEOs tend to have advanced degrees and multiple academic credentials under their belt. But Sean McClain started Absc ...
Absci CEO and founder Sean McClain. (Absci Photo) Absci, a Vancouver, Wash.-based company developing technologies to accelerate the process of drug discovery, announced today that it plans to go public via an IPO. The company’s platform is built to design and generate protein-based drug candida ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|